LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Variant classification summary
NM_000059.4:c.598A>G
BRCA2
· NP_000050.3:p.(Thr200Ala)
· NM_000059.4
GRCh37: chr13:32900717 A>G
·
GRCh38: chr13:32326580 A>G
Gene:
BRCA2
Transcript:
NM_000059.4
Final call
VUS
BP1 strong
Variant details
Gene
BRCA2
Transcript
NM_000059.4
Protein
NP_000050.3:p.(Thr200Ala)
gnomAD AF
8.064956399604941e-06 (v4.1)
ClinVar
Uncertain significance
OncoKB
Unknown Oncogenic Effect
Classification rationale
Interpretation summary
Generated evidence synthesis
1
VUS: BP1 Strong is met because residue 200 is outside the defined BRCA2 functional domains and SpliceAI maximum delta is 0.073.
2
VUS: no additional benign or pathogenic criterion is met to complete an ENIGMA classification combination.
Final determination:
ENIGMA Table 3 does not permit Likely Benign from BP1 Strong alone without additional benign evidence, and with no pathogenic combination met the final call is VUS.
Criteria assessment
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
| Criterion | Status | Rationale | Evidence used |
|---|---|---|---|
| PVS1 | N/A | Not applicable: c.598A>G is a missense substitution, whereas ENIGMA PVS1 applies to null variants such as nonsense, frameshift, canonical splice-site, initiation-codon, or exon-deletion variants. |
cspec
vcep_specifications_v1_2_2024_11_18
vcep_appendices_v1_2_2024_11_18
vcep_specifications_table4_v1_2_2024_11_18
|
| PS1 | Not met | Not met: no previously classified pathogenic variant producing the same p.Thr200Ala substitution was identified for the PS1 comparator requirement. |
cspec
vcep_supplementarytables_v1_2_2024_11_18
vcep_pmid_31853058_brca2_clinical_history_lr
|
| PS2 | N/A | Not applicable: the BRCA2 VCEP explicitly says not to use PS2 because de novo occurrences lack calibrated predictive capacity for relatively common BRCA1/2-related cancers. |
cspec
vcep_specifications_v1_2_2024_11_18
|
| PS3 | Not assessed | Not assessed: no calibrated damaging protein assay result specific to c.598A>G or p.(Thr200Ala) was found in the governing VCEP sources. |
cspec
vcep_specifications_v1_2_2024_11_18
vcep_appendices_v1_2_2024_11_18
vcep_specifications_table9_v1_2_2024_11_18
vcep_humu_40_1557_s001
vcep_supplementarytables_v1_2_2024_11_18
PMID:29988080
|
| PS4 | Not assessed | Not assessed: no variant-specific case-control counts or OR/p-value/95% CI were available to test the VCEP PS4 thresholds (OR ≥4; lower CI >2.0; p ≤0.05). |
cspec
vcep_supplementarytables_v1_2_2024_11_18
vcep_humu_40_1557_s001
|
| PM1 | N/A | Not applicable: ENIGMA designates PM1 N/A, and residue 200 lies outside its BRCA2 domains at aa 10-40 and aa 2481-3186. |
cspec
vcep_specifications_v1_2_2024_11_18
vcep_appendices_v1_2_2024_11_18
|
| PM2 | Not assessed | Not assessed: the variant is absent from non-cancer gnomAD v2.1/v3.1, but required regional average read depth of at least 25 is unavailable. |
cspec
gnomad_v2
gnomad_v4
vcep_specifications_v1_2_2024_11_18
vcep_appendices_v1_2_2024_11_18
vcep_supplementarytables_v1_2_2024_11_18
vcep_humu_40_1557_s001
|
| PM3 | Not assessed | Not assessed: no documented Fanconi Anemia phenotype with a same-gene pathogenic/likely pathogenic co-occurring variant and qualifying phase or homozygous observation was available. |
vcep_specifications_v1_2_2024_11_18
cspec
|
| PM4 | N/A | Not applicable: PM4 is restricted by ENIGMA to in-frame insertion/deletion protein-length changes or stop-loss variants, not the c.598A>G missense substitution. |
cspec
vcep_specifications_v1_2_2024_11_18
|
| PM5 | N/A | Not applicable: ENIGMA excludes classic missense PM5 and limits its repurposed form to pathogenic PTC comparisons, whereas c.598A>G is missense. |
cspec
vcep_specifications_v1_2_2024_11_18
vcep_supplementarytables_v1_2_2024_11_18
|
| PM6 | N/A | Not applicable: the BRCA2 VCEP explicitly says not to use PM6 because de novo occurrences lack calibrated predictive capacity for relatively common BRCA1/2-related cancers. |
cspec
vcep_specifications_v1_2_2024_11_18
|
| PP1 | Not assessed | Not assessed: no quantitative co-segregation LR is available, and the available clinical-history LR is 1.277769323983238 rather than a segregation measure. |
cspec
vcep_specifications_v1_2_2024_11_18
vcep_pmid_31853058_brca2_clinical_history_lr
PMID:31853058
|
| PP2 | N/A | Not applicable: ENIGMA states missense variants are not a common mechanism of pathogenicity for BRCA1 and BRCA2. |
cspec
vcep_specifications_v1_2_2024_11_18
|
| PP3 | Not met | Not met: SpliceAI maximum delta 0.073 is below the ENIGMA PP3 splicing threshold of 0.2 for missense variants. |
cspec
vcep_specifications_v1_2_2024_11_18
spliceai
|
| PP4 | N/A | Not applicable: Li et al. clinical-history LR 1.27777 is below the VCEP PP4 supporting threshold, 1.27777 ≥ 2.08? no. |
cspec
vcep_pmid_31853058_brca2_clinical_history_lr
PMID:31853058
|
| PP5 | N/A | Not applicable: the ENIGMA specification explicitly says PP5 is not to be used for this VCEP framework. |
cspec
clinvar
|
| BA1 | Not met | Not met: gnomAD v4.1 grpmax FAF is 6.16e-06, below the ENIGMA BA1 threshold of 0.001, with no non-cancer v2.1/v3.1 observation. |
cspec
gnomad_v2
gnomad_v4
vcep_specifications_v1_2_2024_11_18
vcep_appendices_v1_2_2024_11_18
vcep_supplementarytables_v1_2_2024_11_18
vcep_humu_40_1557_s001
|
| BS1 | Not met | Not met: gnomAD v4.1 grpmax FAF is 6.16e-06, below the ENIGMA BS1 Supporting lower boundary of 0.00002. |
cspec
gnomad_v2
gnomad_v4
vcep_specifications_v1_2_2024_11_18
vcep_appendices_v1_2_2024_11_18
vcep_supplementarytables_v1_2_2024_11_18
vcep_humu_40_1557_s001
|
| BS2 | Not assessed | Not assessed: gnomAD reports 0 homozygotes, but no qualifying healthy-adult or phenotyped-cohort BS2 observation with VCEP points is available. |
cspec
gnomad_v4
vcep_specifications_v1_2_2024_11_18
vcep_appendices_v1_2_2024_11_18
vcep_supplementarytables_v1_2_2024_11_18
vcep_humu_40_1557_s001
|
| BS3 | Not assessed | Not assessed: no calibrated benign protein-function result specific to c.598A>G or p.(Thr200Ala) was found in the governing VCEP sources. |
cspec
vcep_specifications_v1_2_2024_11_18
vcep_appendices_v1_2_2024_11_18
vcep_specifications_table9_v1_2_2024_11_18
vcep_humu_40_1557_s001
vcep_supplementarytables_v1_2_2024_11_18
PMID:29988080
|
| BS4 | Not assessed | Not assessed: no variant-specific quantitative non-segregation LR or affected-family-member data are available to compare with the VCEP's supporting threshold of LR ≤0.48:1. |
cspec
vcep_specifications_v1_2_2024_11_18
|
| BP1 | Met | Met at strong: residue 200 is outside aa 10-40 and 2481-3186, with SpliceAI maximum delta 0.073 meeting the ≤0.1 threshold. |
cspec
vcep_specifications_v1_2_2024_11_18
spliceai
|
| BP2 | N/A | Not applicable: ENIGMA explicitly says BP2 is not used and applies it only in the context of BS2. |
vcep_specifications_v1_2_2024_11_18
cspec
|
| BP3 | N/A | Not applicable: BP3 is restricted to in-frame deletions/insertions, whereas c.598A>G causes the missense substitution p.(Thr200Ala). |
cspec
vcep_specifications_v1_2_2024_11_18
vcep_appendices_v1_2_2024_11_18
|
| BP4 | N/A | Not applicable: p.Thr200Ala is a missense variant outside both ENIGMA-defined BRCA2 functional domains covered by the BP4 missense rule. |
cspec
vcep_specifications_v1_2_2024_11_18
spliceai
bayesdel
|
| BP5 | Not met | Not met: Li et al. clinical-history LR 1.27777 does not satisfy the VCEP BP5 supporting inequality, 1.27777 ≤ 0.48? no. |
cspec
vcep_pmid_31853058_brca2_clinical_history_lr
PMID:31853058
|
| BP6 | N/A | Not applicable: the ENIGMA specification explicitly says BP6 is not to be used for this VCEP framework. |
cspec
|
| BP7 | Not assessed | Not assessed: BP7_Strong (RNA) covers missense variants outside domains but requires a qualifying mRNA-only assay, which is unavailable for p.Thr200Ala. |
cspec
vcep_specifications_v1_2_2024_11_18
spliceai
|
Disclaimer:
The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.